ondansetron has been researched along with aprepitant in 79 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (29.11) | 29.6817 |
| 2010's | 47 (59.49) | 24.3611 |
| 2020's | 9 (11.39) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Borms, M; Carides, AD; Cocquyt, V; De Smet, M; Decramer, ML; Eldridge, K; Gertz, BJ; O'Brien, M; Reinhardt, RR; Schellens, JH; Van Aelst, F; Van Belle, S; Verbeke, L | 1 |
| Brestan, E; Bui, B; Carides, AD; De Smet, M; Decramer, ML; Eldridge, K; Evans, JK; Garin, AM; Gertz, BJ; Lichinitser, MR; Michiels, N; Navari, RM; Reinhardt, RR; Riviere, A; Thant, M; Van Belle, S | 1 |
| Carides, AD; Chawla, SP; Elmer, ME; Evans, JK; Gralla, RJ; Grunberg, SM; Hesketh, PJ; Horgan, KJ; Rittenberg, C; Schmidt, C; Taylor, A | 1 |
| Aapro, M; Carides, AD; Evans, JK; Hargreaves, R; Hesketh, PJ; Horgan, KJ; Naylor, RJ; Tattersall, FD; Van Belle, S | 1 |
| Cai, B; Carides, AD; Chawla, SP; Elmer, M; Grunberg, SM; Horgan, K; Martin, AR; Pearson, JD; Schmidt, C | 1 |
| Blum, RA; Busillo, J; Goldberg, MR; Gottesdiener, KM; Greenberg, HE; Hesney, M; Hustad, CM; Kraft, WK; Lates, C; Majumdar, A; McCrea, J; Murphy, MG; Orlowski, LH; Panebianco, D; Petty, KJ; Van Buren, S; Waldman, SA | 1 |
| Beck, K; Carides, AD; Chawla, SP; de Wit, R; Elmer, ME; Evans, JK; Gralla, RJ; Grunberg, SM; Hesketh, PJ; Horgan, KJ; Ianus, J; Reines, S; Roila, F; Warr, DG | 1 |
| Bohidar, N; Eisenberg, PD; Gabriel, M; Gralla, RJ; Grunberg, SM; Herrstedt, J; Hesketh, PJ; Horgan, KJ; Hustad, CM; Klinger, G; Muss, HB; Raftopoulos, H; Rodgers, A; Skobieranda, F; Warr, DG | 1 |
| Carides, AD; de Wit, R; Evans, JK; Gralla, RJ; Guoguang-Ma, J; Herrstedt, J; Horgan, KJ; Ianus, J | 1 |
| Aapro, MS; Ahmed, T; Chan, CY; Giezek, H; Jordan, K; Kim, HK; Park, K; Poli-Bigelli, S; Schmoll, HJ; von Pawel, J | 1 |
| de Bruijn, P; de Wit, R; Freedman, SJ; Gambale, JJ; Li, S; Loos, WJ; Murphy, GM; Van Dyck, K; van Noort, C; Verweij, J | 1 |
| Berger, K; Davies, G; Deuson, R; Ehlken, B; Ihbe-Heffinger, A; Krobot, KJ; Lordick, F; Pellissier, J | 1 |
| Cavaretta, M; Noviasky, J | 1 |
| Apfel, CC; Carides, AD; Evans, JK; Gan, TJ; Habib, AS; Horgan, KJ; Knighton, J; Kovac, A; Lawson, FC; Minkowitz, H; Philip, BK; Singla, N; Zhang, H | 1 |
| Carides, AD; Chelly, JE; Diemunsch, P; Eberhart, L; Evans, JK; Gan, TJ; Girao, MJ; Irwin, MG; Lawson, FC; Philip, BK; Pueyo, J; Reiss, T | 1 |
| Wilkes, G | 1 |
| Carides, A; Diemunsch, P; Lines, C; McKeon, B; Reiss, T | 1 |
| Chan, SL; Ho, WM; Hui, EK; Koh, J; Kwan, WH; Lam, KC; Lau, W; Lee, KK; Mo, FK; Mok, TS; Poon, AN; Suen, JJ; Yeo, W; Yeung, WK; Zee, B | 1 |
| Carides, AD; Chawla, S; Chua, V; Devandry, S; Evans, JK; Gore, L; Hemenway, M; Oxenius, B; Petrilli, A; Schissel, D; Taylor, A; Valentine, J | 1 |
| Szántó, J; Tóth, J | 1 |
| Auger, A; Combes, JD; Favier, B; Galy, G; Labidi, SI; Latour, JF; Tissier, F | 1 |
| Bassam, A; Pikó, B | 1 |
| Boice, JA; Brown, C; Carides, A; Hardwick, JS; Jordan, K; Rapoport, BL; Schmoll, HJ; Taylor, A; Webb, T | 1 |
| DiIorio, TM; Hewitt, AM; Parvizi, J; Sharkey, PF | 1 |
| Carides, AD; Street, JC; Warr, DG | 1 |
| Carides, AD; Hesketh, PJ; Street, JC; Warr, DG | 1 |
| Braun, MP; Dean, D; Fedgchin, M; Gargano, C; Gottesdiener, KM; Greenberg, HE; Kraft, WK; Majumdar, A; Murphy, MG; Panebianco, D; Pequignot, E; Petty, KJ; Stoch, SA; Valentine, J | 1 |
| Borel, CO; Gan, TJ; Habib, AS; Keifer, JC; White, WD | 1 |
| Beckford, E; Boice, JA; Carides, A; Chua, D; DeVandry, S; Dinis, J; Grunberg, S; Hardwick, JS; Herrstedt, J; Maru, A; Roila, F; Taylor, A | 1 |
| Egashira, N; Kawashiri, T; Kurobe, K; Matsushita, N; Oishi, R; Tatsushima, Y; Yano, T | 1 |
| Barnes, LR; Ibinson, JW; Milord, PJ; Phelps, AL; Romeo, RC; Sah, N; Vallejo, MC; Williams, BA | 1 |
| Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A | 1 |
| Burger, DM; van Herpen, CML; Verwimp-Hoeks, MPA | 1 |
| Antor, A; Bergese, S; Fernandez, S; Uribe, A; Viloria, A | 1 |
| Fletcher-Gonzalez, D; Fox-Geiman, MP; Go, A; Kiley, K; Parthasarathy, M; Porter, N; Rodriguez, TE; Rychlik, K; Smith, SE; Stiff, PJ | 1 |
| Bannerji, R; Kantesaria, B; Mita, M; Poon, J; Shapiro, GI; Small, K; Statkevich, P; Tzontcheva, A; Zhang, D; Zhu, Y | 1 |
| Bazakas, A; Ladizinski, B; Olsen, EA | 1 |
| Berger, MJ; Blazer, MA; Crawford, BS; Flynn, JM; Griffith, NL; Layman, RM; Lustberg, MB; Mrozek, E; Phillips, GS; Ramaswamy, B; Shapiro, CL; Wenzell, CM; Wesolowski, R | 1 |
| Bourdon, F; Duhaut, M; Foulon, C; Lecoeur, M; Odou, P; Vaccher, C | 1 |
| Goudra, BG; Ochroch, EA; Singh, PM; Sinha, AC; Williams, NW | 1 |
| Kakiuchi, H; Kawarai-Shimamura, A; Kuwagata, M; Orito, K | 1 |
| Biondo, L; Bodge, M; Paul, S; Shillingburg, A | 1 |
| Bourdon, F; Foulon, C; Lecoeur, M; Odou, P; Vaccher, C | 1 |
| Barrais, L; Castagné, V; Goineau, S; Guillaume, P | 1 |
| Rapoport, BL | 1 |
| Preskorn, SH | 1 |
| Badar, T; Borthakur, G; Cortes, J; Ferrajoli, A; Garcia-Manero, G; Kadia, T; Kantarjian, H; Mattiuzzi, G; O'Brien, S; Poku, R; Wierda, W | 1 |
| Chow, E; DeAngelis, C; Hunyh, L; McDonald, R; Pasetka, M; Raman, S; Rowbottom, L | 1 |
| Bakhshi, S; Batra, A; Biswas, B; Dhawan, D; Paul, R; Sreenivas, V | 1 |
| Du, BX; Liu, M; Shi, XY; Sui, B; Xu, FY; Zhang, H; Zou, Z | 1 |
| Jahn, F; Jahn, P; Jordan, K; Riesner, A; Sieker, F; Vordermark, D | 1 |
| Horita, H; Hotta, H; Kato, R; Kitamura, H; Kunishima, Y; Masumori, N; Takahashi, A; Takei, F | 1 |
| Bouganim, N; Clemons, M; Dranitsaris, G; Mazzarello, S; Smith, S; Vandermeer, L | 1 |
| Liu, RR; Liu, ZT; Yang, YL; Yang, ZH; Yue, W | 1 |
| Ahn, JS; Cho, YH; Jang, JS; Kang, JH; Kim, HJ; Kim, JS; Kim, SW; Kim, SY; Kim, YS; Ko, YH; Lee, HW; Lee, NR; Lee, SN; Lee, SR; Park, KU; Shin, SW; Song, EK; Yun, HJ | 1 |
| Ham, SY; Kim, EH; Lee, JS; Park, WS; Shim, YH; Son, MJ | 1 |
| Hou, F; Le, Q; Li, H; Li, W; Liu, S; Shi, Q; Zheng, L; Zong, S | 1 |
| Asada, K; Enomoto, N; Fujisawa, T; Hayakawa, H; Imokawa, S; Inui, N; Karayama, M; Kuroishi, S; Masuda, M; Nakamura, Y; Suda, T; Suzuki, S; Toyoshima, M; Watanabe, H; Yamada, T; Yokomura, K | 1 |
| Birrer, MJ; Spriggs, DR; Wilbur, MB | 1 |
| Song, Z; Wang, H; Yang, F; Zhang, H; Zhang, M; Zhao, K | 1 |
| Bourdon, F; Foulon, C; Kouach, M; Lecoeur, M; Leconte, L; Odou, P; Ultré, V; Vaccher, C | 1 |
| Ahn, MJ; Cho, CH; Cho, EK; Jang, JS; Jung, H; Kim, DJ; Kim, JE; Kim, JW; Lee, KY; Lee, MA; Lim, MC; Min, KW; Sung, YL; Sym, SJ | 1 |
| D'Athayde Rodrigues, F; Ferreira, MAP; Moreira, LB; Okumura, LM | 1 |
| Ades, S; Ashikaga, T; Blackstock, W; Halyard, M; Heimann, R; Kumar, S; Wilson, K | 1 |
| Kellogg, TA; Martin, EE; Schroeder, DR; Sprung, J; Therneau, IW; Weingarten, TN | 1 |
| Abbas, N; Abdel-Malek, R; Fawzy, R; Ismail, M; Safwat, E; Salem, DS; Shohdy, KS | 1 |
| DiCristina, C; Green, S; Kang, HJ; Loftus, S; Pong, A; Zwaan, CM | 1 |
| Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S | 1 |
| Navari, RM | 1 |
| Burckart, G; Garimella, N; Griebel, D; Heinrichs, MT; Kim, I; Krudys, K; Kumar, S; Mehrotra, N; Momper, JD; Mulberg, AE; Mulugeta, Y; Nelson, R; Reaman, G; Sachs, H; Sinha, V; Yao, L; Zineh, I | 1 |
| Chan, VT; Cheung, M; Lai, KT; Lam, DC; Lau, TK; Li, L; Mo, FK; Ng, KP; Pang, E; Soo, WM; Suen, JJ; Tang, NL; Tong, M; Tse, T; Wong, A; Yeo, W; Yeung, EW; Yeung, VT | 1 |
| Akewanlop, C; Danchaivijitr, P; Ithimakin, S; Korphaisarn, K; Laocharoenkiat, A; Nimmannit, A; Soparattanapaisarn, N; Techawattanawanna, S; Theeratrakul, P | 1 |
| Morio, K; Tsujimoto, Y; Watanabe, J | 1 |
| Affronti, ML; Herndon, JE; Patel, MP | 1 |
| Aghazarian, GS; Ghanem, M; Jawad, MA; Lastrapes, L; Lind, R; Motola, D; Perry, M; Singletary, N; Teixeira, AF | 1 |
| Chen, X; He, H; Hu, W; Liao, Y; Liu, W; Liu, Y; Pan, Z; Wang, X; Zheng, F; Zhong, H | 1 |
10 review(s) available for ondansetron and aprepitant
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Granisetron; Humans; Morpholines; Neoplasms; Neurokinin-1 Receptor Antagonists; Neurotransmitter Agents; Ondansetron; Prodrugs; Serotonin; Serotonin Antagonists; Substance P; Vomiting | 2003 |
Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects.
Topics: Adult; Antiemetics; Aprepitant; Area Under Curve; Cross-Over Studies; Drug Interactions; Female; Granisetron; Half-Life; Humans; Male; Middle Aged; Morpholines; Ondansetron; Randomized Controlled Trials as Topic | 2003 |
Health outcomes and cost-effectiveness of aprepitant in outpatients receiving antiemetic prophylaxis for highly emetogenic chemotherapy in Germany.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Health Resources; Humans; Morpholines; Multicenter Studies as Topic; Nausea; Neoplasms; Ondansetron; Randomized Controlled Trials as Topic; Treatment Outcome; Vomiting | 2007 |
[Prophylaxis of chemotherapy-induced vomiting and nausea].
Topics: Adrenal Cortex Hormones; Antiemetics; Antineoplastic Agents; Aprepitant; Granisetron; Humans; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Ondansetron; Primary Prevention; Serotonin 5-HT3 Receptor Antagonists; Time Factors; Vomiting | 2008 |
[Treatment of tumor therapy-induced nausea and vomiting].
Topics: Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Drug Therapy, Combination; Humans; Methylprednisolone; Metoclopramide; Morpholines; Nausea; Neoplasms; Ondansetron; Practice Guidelines as Topic; Selective Serotonin Reuptake Inhibitors; Vomiting | 2009 |
Neurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysis.
Topics: Antiemetics; Aprepitant; Dose-Response Relationship, Drug; Humans; Morpholines; Neurokinin-1 Receptor Antagonists; Ondansetron; Postoperative Nausea and Vomiting; Randomized Controlled Trials as Topic | 2015 |
Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Granisetron; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Network Meta-Analysis; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Spiro Compounds; Treatment Outcome; Vomiting | 2016 |
Aprepitant in pediatric patients using moderate and highly emetogenic protocols: a systematic review and meta-analyses of randomized controlled trials.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Aprepitant; Child; Child, Preschool; Dexamethasone; Drug Therapy, Combination; Humans; Infant; Morpholines; Nausea; Neoplasms; Ondansetron; Randomized Controlled Trials as Topic; Risk Factors; Vomiting; Young Adult | 2017 |
The efficacy of aprepitant for the prevention of postoperative nausea and vomiting: A meta-analysis.
Topics: Antiemetics; Aprepitant; Dexamethasone; Humans; Morpholines; Ondansetron; Postoperative Nausea and Vomiting; Vomiting | 2023 |
42 trial(s) available for ondansetron and aprepitant
| Article | Year |
|---|---|
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
Topics: Acetals; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Patient Satisfaction; Prodrugs; Vomiting | 2001 |
Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Neoplasms; Neurokinin-1 Receptor Antagonists; Ondansetron; Vomiting | 2002 |
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Administration, Oral; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Ondansetron; Treatment Outcome; Vomiting | 2003 |
Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Ondansetron; Receptors, Neurokinin-1; Surveys and Questionnaires; Vomiting | 2003 |
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Gr
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Ondansetron; Placebos; Treatment Outcome; Vomiting | 2003 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Morpholines; Nausea; Ondansetron; Vomiting | 2005 |
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two Phase III randomize
Topics: Adrenal Cortex Hormones; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Cyclophosphamide; Dexamethasone; Female; Humans; Male; Morpholines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Ondansetron; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2005 |
Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Neoplasms; Ondansetron; Patient Selection | 2006 |
A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aprepitant; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Ondansetron; Postoperative Nausea and Vomiting; Receptors, Neurokinin-1 | 2007 |
Single-dose aprepitant vs ondansetron for the prevention of postoperative nausea and vomiting: a randomized, double-blind phase III trial in patients undergoing open abdominal surgery.
Topics: Abdomen; Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Aprepitant; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Ondansetron; Postoperative Nausea and Vomiting; Severity of Illness Index; Treatment Outcome | 2007 |
A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Carcinoma, Ductal, Breast; China; Dexamethasone; Double-Blind Method; Female; Humans; Middle Aged; Morpholines; Nausea; Ondansetron; Quality of Life; Vomiting | 2009 |
Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.
Topics: Adolescent; Antineoplastic Agents; Aprepitant; Area Under Curve; Child; Dexamethasone; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Humans; Metabolic Clearance Rate; Morpholines; Nausea; Neutropenia; Ondansetron; Placebos; Treatment Outcome; Vomiting; Young Adult | 2009 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Ondansetron; Prospective Studies; Treatment Outcome; Vomiting | 2010 |
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Breast Neoplasms, Male; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Morpholines; Multivariate Analysis; Nausea; Neurokinin-1 Receptor Antagonists; Ondansetron; Prognosis; Risk Factors; Vomiting | 2011 |
Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Logistic Models; Male; Middle Aged; Morpholines; Multivariate Analysis; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Ondansetron; Serotonin 5-HT3 Receptor Antagonists; Time Factors; Vomiting | 2011 |
Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant.
Topics: Adult; Antiemetics; Aprepitant; Cross-Over Studies; Cytochrome P-450 CYP3A; Dexamethasone; Double-Blind Method; Drug Interactions; Female; Humans; Male; Midazolam; Morpholines; Ondansetron | 2011 |
A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy.
Topics: Adult; Aprepitant; Craniotomy; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Ondansetron; Postoperative Nausea and Vomiting; Prospective Studies | 2011 |
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Treatment Outcome; Vomiting | 2011 |
Aprepitant plus ondansetron compared with ondansetron alone in reducing postoperative nausea and vomiting in ambulatory patients undergoing plastic surgery.
Topics: Adult; Ambulatory Surgical Procedures; Antiemetics; Aprepitant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Ondansetron; Plastic Surgery Procedures; Postoperative Nausea and Vomiting; Prospective Studies | 2012 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Melphalan; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Transplantation, Autologous; Treatment Outcome; Vomiting | 2011 |
Aprepitant versus ondansetron in preoperative triple-therapy treatment of nausea and vomiting in neurosurgery patients: study protocol for a randomized controlled trial.
Topics: Antiemetics; Aprepitant; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Humans; Morpholines; Neurosurgical Procedures; Ohio; Ondansetron; Postoperative Nausea and Vomiting; Promethazine; Research Design; Treatment Outcome | 2012 |
Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens.
Topics: Adult; Aged; Antiemetics; Aprepitant; Dexamethasone; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Morpholines; Ondansetron; Postoperative Nausea and Vomiting; Prospective Studies; Severity of Illness Index; Transplantation, Autologous; Transplantation, Homologous | 2013 |
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Antiemetics; Antineoplastic Agents; Aprepitant; Area Under Curve; Bridged Bicyclo Compounds, Heterocyclic; Cross-Over Studies; Cyclic N-Oxides; Cyclin-Dependent Kinases; Dexamethasone; Drug Administration Schedule; Female; Half-Life; Humans; Indolizines; Infusions, Intravenous; Linear Models; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Ondansetron; Pyridinium Compounds; Treatment Failure; Vomiting | 2012 |
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Ondansetron; Palonosetron; Pilot Projects; Prospective Studies; Quinuclidines; Vomiting | 2013 |
Aprepitant's prophylactic efficacy in decreasing postoperative nausea and vomiting in morbidly obese patients undergoing bariatric surgery.
Topics: Adult; Antiemetics; Aprepitant; Bariatric Surgery; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Laparoscopy; Male; Middle Aged; Morpholines; Obesity, Morbid; Ondansetron; Patient Satisfaction; Postoperative Nausea and Vomiting; Prospective Studies; Treatment Outcome | 2014 |
Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Body Weight; Child; Child, Preschool; Dexamethasone; Drug Therapy, Combination; Female; Humans; Incidence; Infant; Male; Morpholines; Nausea; Neoplasms; Ondansetron; Prospective Studies; Remission Induction; Severity of Illness Index; Treatment Outcome; Vomiting | 2014 |
Efficacy of a triple antiemetic regimen with aprepitant for the prevention of chemotherapy-induced nausea and vomiting: effects of gender, age, and region.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Prospective Studies; Sex Factors; Treatment Outcome; Vomiting; Young Adult | 2014 |
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytara
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cytarabine; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Treatment Outcome; Vomiting | 2015 |
Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Intravenous; Adolescent; Anti-Inflammatory Agents; Antiemetics; Aprepitant; Child; Child, Preschool; Dexamethasone; Double-Blind Method; Female; Humans; Induction Chemotherapy; Male; Morpholines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Ondansetron; Ontario; Remission Induction; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2015 |
Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Chemoradiotherapy; Cisplatin; Dexamethasone; Drug Therapy, Combination; Esophageal Neoplasms; Female; Head and Neck Neoplasms; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Ondansetron; Prospective Studies; Serotonin Antagonists; Tropisetron; Uterine Cervical Neoplasms; Vomiting | 2015 |
Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Dexamethasone; Female; Humans; Middle Aged; Morpholines; Nausea; Ondansetron; Outcome Assessment, Health Care; Practice Guidelines as Topic; Risk Factors; Vomiting | 2016 |
Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benzimidazoles; Dexamethasone; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Ondansetron; Prospective Studies; Single-Blind Method; Treatment Outcome; Vomiting | 2015 |
Aprepitant for antiemesis after laparoscopic gynaecological surgery: A randomised controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Analgesia, Patient-Controlled; Analgesics, Opioid; Antiemetics; Aprepitant; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fentanyl; Gynecologic Surgical Procedures; Hospitals, University; Humans; Kaplan-Meier Estimate; Laparoscopy; Middle Aged; Morpholines; Neurokinin-1 Receptor Antagonists; Ondansetron; Postoperative Nausea and Vomiting; Republic of Korea; Serotonin Antagonists; Time Factors; Treatment Outcome; Young Adult | 2016 |
Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dexamethasone; Female; Granisetron; Humans; Lung Neoplasms; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Paclitaxel; Pemetrexed; Vomiting | 2016 |
Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial.
Topics: Activities of Daily Living; Adult; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Drug Therapy, Combination; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Prednisone; Quality of Life; Treatment Outcome; Vomiting | 2017 |
Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cyclophosphamide; Dexamethasone; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Ondansetron; Vomiting; Young Adult | 2017 |
Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT).
Topics: Abdomen; Aged; Antiemetics; Aprepitant; Dose Fractionation, Radiation; Female; Humans; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Radiotherapy; Vomiting | 2017 |
Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Chemoprevention; Cisplatin; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Pilot Projects; Time Factors; Treatment Outcome; Vomiting | 2017 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group.
Topics: Adolescent; Age Factors; Antiemetics; Antineoplastic Agents; Aprepitant; Child; Child, Preschool; Double-Blind Method; Female; Humans; Infant; Male; Nausea; Neoplasms; Ondansetron; Vomiting | 2018 |
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans; Male; Middle Aged; Nausea; Ondansetron; Quality of Life; Temozolomide; Vomiting | 2020 |
A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; China; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Middle Aged; Nausea; Olanzapine; Ondansetron; Vomiting | 2020 |
Randomized, double-blind, placebo-controlled study of aprepitant versus two dosages of olanzapine with ondansetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving high-emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Chemoprevention; Cisplatin; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Doxorubicin; Drug Therapy, Combination; Emetics; Female; Humans; Induction Chemotherapy; Male; Middle Aged; Nausea; Neoplasms; Olanzapine; Ondansetron; Placebos; Quality of Life; Treatment Outcome; Vomiting; Young Adult | 2020 |
27 other study(ies) available for ondansetron and aprepitant
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.
Topics: Antiemetics; Antineoplastic Agents, Phytogenic; Aprepitant; Area Under Curve; Cross-Over Studies; Dexamethasone; Drug Therapy, Combination; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Morpholines; Neoplasms; Ondansetron; Vinblastine; Vinorelbine | 2007 |
Study flaw in comparisons of aprepitant and ondansetron.
Topics: Antiemetics; Aprepitant; Clinical Trials as Topic; Humans; Morpholines; Ondansetron; Postoperative Nausea and Vomiting; Research Design | 2007 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipation; Diarrhea; Drug Interactions; Dyspepsia; Fatigue; Fever; Granisetron; Headache; Hiccup; Humans; Indoles; Injections, Intravenous; Isoquinolines; Morpholines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Vomiting | 2007 |
Comparisons of aprepitant and ondansetron.
Topics: Antiemetics; Aprepitant; Chemoprevention; Clinical Trials, Phase III as Topic; Humans; Morpholines; Ondansetron; Postoperative Nausea and Vomiting; Treatment Outcome | 2007 |
[Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Female; Humans; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Prednisolone; Prospective Studies; Vomiting | 2009 |
Antiemesis after total joint arthroplasty: does a single preoperative dose of aprepitant reduce nausea and vomiting?
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Aprepitant; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Case-Control Studies; Drug Administration Schedule; Female; Humans; Length of Stay; Male; Middle Aged; Morpholines; Ondansetron; Postoperative Nausea and Vomiting; Preoperative Care; Retrospective Studies; Severity of Illness Index; Time Factors; Treatment Outcome | 2010 |
Pemirolast reduces cisplatin-induced kaolin intake in rats.
Topics: Animals; Antineoplastic Agents; Aprepitant; Biological Transport; Body Weight; Cisplatin; Dexamethasone; Eating; Kaolin; Male; Morpholines; Ondansetron; Pyridines; Pyrimidinones; Rats; Substance P | 2011 |
Aprepitant quetiapine: a clinically significant drug interaction in a patient treated for head and neck cancer.
Topics: Adult; Antidepressive Agents; Antiemetics; Antineoplastic Agents; Aprepitant; Carcinoma; Chemoradiotherapy; Cisplatin; Citalopram; Depression; Dexamethasone; Dibenzothiazepines; Drug Interactions; Humans; Laryngeal Neoplasms; Male; Morpholines; Ondansetron; Quetiapine Fumarate | 2012 |
Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma.
Topics: Aged; Antipruritics; Aprepitant; Drug Therapy, Combination; Female; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; Morpholines; Neurokinin-1 Receptor Antagonists; Ondansetron; Pain Measurement; Recombinant Proteins; Substance P | 2012 |
A validated micellar electrokinetic chromatography method for the quantitation of dexamethasone, ondansetron and aprepitant, antiemetic drugs, in organogel.
Topics: Antiemetics; Aprepitant; Chemistry, Pharmaceutical; Chromatography, Micellar Electrokinetic Capillary; Dexamethasone; Gels; Morpholines; Ondansetron | 2013 |
Tranexamic acid induces kaolin intake stimulating a pathway involving tachykinin neurokinin 1 receptors in rats.
Topics: Animals; Antiemetics; Antifibrinolytic Agents; Aprepitant; Area Postrema; Domperidone; Dopamine Antagonists; Kaolin; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Ondansetron; Proto-Oncogene Proteins c-fos; Rats; Rats, Wistar; Receptors, Neurokinin-1; Serotonin Antagonists; Solitary Nucleus; Tranexamic Acid | 2014 |
Complementarity of UV-PLS and HPLC for the simultaneous evaluation of antiemetic drugs.
Topics: Administration, Cutaneous; Antiemetics; Aprepitant; Chromatography, High Pressure Liquid; Dexamethasone; Gels; Least-Squares Analysis; Limit of Detection; Morpholines; Ondansetron; Spectrophotometry, Ultraviolet | 2014 |
Automated analysis of delayed emesis in the telemetered ferret: detection of synergistic effects of aprepitant and ondansetron.
Topics: Animals; Antiemetics; Antineoplastic Agents; Aprepitant; Automation; Cisplatin; Drug Synergism; Ferrets; Male; Morpholines; Ondansetron; Telemetry; Time Factors; Vomiting | 2014 |
CNS drug development: lessons from the development of ondansetron, aprepitant, ramelteon, varenicline, lorcaserin, and suvorexant. Part I.
Topics: Aprepitant; Azepines; Benzazepines; Central Nervous System Agents; Drug Discovery; History, 20th Century; History, 21st Century; Humans; Indenes; Morpholines; Neurotransmitter Agents; Ondansetron; Quinoxalines; Triazoles; Varenicline | 2014 |
Efficacy of granisetron and aprepitant in a patient who failed ondansetron in the prophylaxis of radiation induced nausea and vomiting: a case report.
Topics: Antiemetics; Aprepitant; Bone Neoplasms; Breast Neoplasms; Female; Granisetron; Humans; Middle Aged; Morpholines; Nausea; Neoplasm Metastasis; Ondansetron | 2015 |
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dexamethasone; Drug Therapy, Combination; Female; Gemcitabine; Granisetron; Humans; Isoquinolines; Kidney Neoplasms; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vomiting | 2015 |
[Effect of Ju-Pi-Tang on Cisplatin-induced Emetic Model in Minks].
Topics: Animals; Antiemetics; Aprepitant; Brain; Cisplatin; Disease Models, Animal; Drugs, Chinese Herbal; Ileum; Mink; Morpholines; Ondansetron; Vomiting | 2015 |
CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Dexamethasone; Drug Therapy, Combination; Female; Humans; Middle Aged; Morpholines; Nausea; Olanzapine; Ondansetron; Vomiting | 2016 |
Evaluation of Pentravan
Topics: Administration, Cutaneous; Animals; Antiemetics; Antineoplastic Agents; Aprepitant; Chemistry, Pharmaceutical; Dexamethasone; Drug Carriers; Humans; Lecithins; Morpholines; Nausea; Ondansetron; Pharmaceutical Vehicles; Swine; Vomiting | 2016 |
The Role of Aprepitant in Prevention of Postoperative Nausea and Vomiting After Bariatric Surgery.
Topics: Adult; Aged; Antiemetics; Aprepitant; Bariatric Surgery; Chemoprevention; Dexamethasone; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Obesity, Morbid; Ondansetron; Postoperative Nausea and Vomiting; Retrospective Studies | 2018 |
Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Ondansetron; Palonosetron; Retrospective Studies; Vomiting | 2020 |
Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy-Induced Nausea and Vomiting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Child; Child, Preschool; Clinical Trials as Topic; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Dosage Calculations; Female; Granisetron; Humans; Infant; Male; Middle Aged; Nausea; Neurokinin-1 Receptor Antagonists; Ondansetron; Palonosetron; Treatment Outcome; United States; United States Food and Drug Administration; Vomiting; Young Adult | 2020 |
Letter referencing "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide".
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patien
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Impact of Emend on Perioperative Bariatric Surgery Antiemetic Utilization, Patient Satisfaction, and Costs.
Topics: Antiemetics; Aprepitant; Bariatric Surgery; Humans; Ondansetron; Patient Satisfaction; Postoperative Nausea and Vomiting; Retrospective Studies | 2023 |